Lewis H. Bender - Jun 29, 2023 Form 3 Insider Report for INTENSITY THERAPEUTICS, INC. (INTS)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Daniel L. Woodard, Attorney-in-Fact
Stock symbol
INTS
Transactions as of
Jun 29, 2023
Transactions value $
$0
Form type
3
Date filed
6/29/2023, 07:56 PM
Next filing
Mar 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding INTS Common Stock, $0.0001 Par Value 2M Jun 29, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding INTS Stock Option (right to buy Common Stock) Jun 29, 2023 Common Stock 75K $9.00 Direct F1
holding INTS Stock Option (right to buy Common Stock) Jun 29, 2023 Common Stock 75K $11.50 Direct F2
holding INTS Stock Option (right to buy Common Stock) Jun 29, 2023 Common Stock 75K $11.50 Direct F3
holding INTS Stock Option (right to buy Common Stock) Jun 29, 2023 Common Stock 75K $9.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested and exercisable.
F2 This option is vested and exercisable with regard to 37,500 shares of Common Stock. This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued employment with Intensity Therapeutics, Inc., in two equal annual installments, beginning on July 31, 2023.
F3 This option is vested and exercisable with regard to 37,500 shares of Common Stock. This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued employment with Intensity Therapeutics, Inc., in two equal annual installments, beginning on August 13, 2023.
F4 This option is vested and exercisable with regard to 18,750 shares of Common Stock. This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued employment with Intensity Therapeutics, Inc., in three equal annual installments beginning on December 13, 2023.

Remarks:

Exhibit 24 - Power of Attorney